Logo

Amersham Confirms Takeover Feeler

Oct 08, 2003

NEW YORK, Oct. 8 (GenomeWeb News) – London-based Amersham today announced that it has received a possible takeover bid.
In a short written statement, Amersham, the diagnostics and healthcare giant, said it has received an approach from an unnamed party that “may or may not lead to an offer for the company as a whole.”

The short statement , available on the company website, said “no agreement has been reached and a further announcement will be made as appropriate.”

The statement was released in response to a sharp rise in its share prices today.

Published reports speculated that the buyer could be companies like Johnson & Johnson or Roche Holding.

The 10,000-employee company has a market capitalization of $7.5 billion.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.